Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT

Background: Around 12,500 cases of Staphylococcus aureus bacteraemia occur each year in the United Kingdom, with an associated mortality of about 30%, yet the evidence guiding optimum management is poor. We hypothesise that adjunctive rifampicin will enhance killing of Staphylococcus aureus early i...

Full description

Bibliographic Details
Main Authors:	Thwaites, GE, Scarborough, M, Szubert, AJ, Concalves, P, Soares, M, Bostock, J, Nsutebu, E, Tilley, R, Cunningham, R, Grieg, J, Wyllie, SA, Wilson, P, Auckland, C, Cairns, J, Ward, D, Lal, P, Guleri, A, Jenkins, N, Sutton, J, Wiselka, M, Armando, G-R, Graham, C, Chadwick, PR, Barlow, G, Gordon, C, Young, B, Meisner, S, McWhinney, P, Price, DA, Harvey, D, Nayar, D, Jeyaratnam, D, Planche, T, Minton, J, Hudson, F, Hopkins, S, Williams, J, Torok, EM, Llewelyn, MJ, Edgeworth, JD, Walker, AS
Format:	Journal article
Published:	NIHR Journals Library 2018

Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT

Similar Items